Roth MKM lowered the firm’s price target on CervoMed (CRVO) to $4 from $45 and keeps a Buy rating on the shares. The company ...

Research is ongoing to find out whether this is the case for other types of dementia, such as dementia with Lewy bodies too. As well as common genes that have a small effect on a person’s risk, there ...

CervoMed (CRVO) announced topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for the treatment of patients with dementia with Lewy bodies. DLB. The trial did not meet ...

CervoMed reports RewinD-LB trial results for neflamapimod in dementia with Lewy bodies, highlighting missed endpoints and ...

CervoMed Inc.’s stock cratered early Tuesday after the biotech company said a midstage trial of a treatment for patients with ...

Black older adults who frequently attend religious services are significantly less likely to develop Alzheimer’s or related ...

CervoMed said on Tuesday its experimental drug for a common degenerative brain disease did not meet the main or secondary ...

CervoMed Inc. (CRVO) announced Tuesday that its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia ...

Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks——Favorable ...

CervoMed on Tuesday said a mid-stage study of its lead program neflamapimod missed its key goals in the degenerative brain disease dementia with Lewy bodies, or DLB.

CervoMed’s ex-Vertex drug has failed to reduce the severity of patients’ dementia in a phase 2 trial, halting plans for a ...

Researchers identified 13 proteins that predicted how quickly or slowly a person's brain aged. (Nature Aging) Midlife anxiety ...